Zavicefta (ceftazidime–avibactam) | Dosering hos voksne

Kun for helsepersonell

Søk

Logg inn

Logg ut

Legemiddel

Terapiområde

Utforsk mer

Materiell

Video/podkast

Nyhetsbrev

Kontakt oss

Om Zavicefta

Virkningsmekanisme

Patogen dekning

Tidlig hensiktsmessig behandling

IDSA anbefaling

Økonomiske holdepunkter

Spørsmål og svar om ZAVICEFTA

Pasientprofiler

HAP/VAP pasient

cUTI pasient

cIAI pasient

Pediatriske pasienter

Spørsmål og svar - FAQs

Effekt

Real-world evidence

Effektdata

Spørsmål og svar om effekt

Sikkerhet

Sikkerhet hos voksne

Sikkerhet hos barn/ungdom

Spørsmål og svar om sikkerhet

Dosering

Dosering hos voksne

Dosering hos barn/ungdom

Spørsmål og svar om dosering

Dosering hos voksne

Normal adult renal function

Adult renal impairment

Tab Number 3

ZAVICEFTA (ceftazidime–avibactam) has consistent dosing across indications, with no dosage adjustments required in the elderly, adult patients with mild renal impairment (estimated CrCl ≥ 51 to ≤80 mL/min) and those with hepatic impairment¹

Recommended dose for adult patients with estimated CrCl ≥51 mL/min^1*

Scroll left to view table

Dosage adjustment is required for patients with renal impairment (estimated CrCl ≤50 mL/min)¹

Recommended dose adjustments in adult patients with estimated CrCl ≤50 mL/min:¹

Scroll left to view table

Listen to Professor Federico Pea

From the Department Of Medical and Surgical Science, Alma Mater Studiorum, University of Bologna, Italy as he discusses PK/PD attributes of ZAVICEFTA in patients.

Explore more

Safety and tolerability

Learn more about ZAVICEFTA’s safety and tolerability in adult and paediatric patients.

Footnotes:

^*The dose of ZAVICEFTA in adult patients with estimated CrCl ≤50 mL/min should be adjusted according to recommended doses. CrCl estimated using the Cockcroft-Gault formula.¹
^†To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.¹
^‡To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.¹
^§The total duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.¹
^‖There is very limited experience with the use of ZAVICEFTA for more than 14 days.¹
^**CrCl estimated using the Cockcroft–Gault formula.¹
^††Dose recommendations are based on PK modelling.¹
^‡‡Dosing of ZAVICEFTA on haemodialysis days should occur after completion of haemodialysis.¹

Abbreviations:

cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end-stage renal disease; HAP, hospital-acquired pneumonia; PK, pharmacokinetic; VAP, ventilator-associated pneumonia.

Reference:

ZAVICEFTA SPC

Preparatomtale

PP-ZVA-NOR-0141 Mai 2023

Dosering

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00

PP-BCP-NOR-0001 juni 2023

Du forlater nå PfizerPro.no

Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.